Ultragenyx Pharmaceutical Inc. Stock
There is no change in the price for Ultragenyx Pharmaceutical Inc. today.
The stock is an absolute favorite of our community with 24 Buy predictions and no Sell predictions.
Based on the current price of 18.3 € the target price of 55 € shows a potential of 200.55% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0.000% | -1.170% | -13.776% | -49.401% | 0.595% | -53.825% | -82.487% |
| United Therapeutics | -1.950% | 5.100% | 15.583% | 73.172% | 15.259% | 145.269% | 200.305% |
| Ionis Pharmaceuticals Inc. | 0.830% | 3.150% | -5.094% | 156.386% | -4.591% | 96.634% | 69.428% |
| Novocure Ltd | -1.770% | -6.613% | -18.944% | -43.226% | -17.406% | -83.122% | -91.730% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target lowered by JPMorgan Chase & Co. from $120.00 to $74.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $128.00 to $79.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced